North East and North Cumbria
ICS Formulary
ICS Formulary
10 Musculoskeletal and joint diseases
10-02-01 Drugs used in neuromuscular disorders
| Ataluren Translarna® |
|
Formulary
|
|
 NICE HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
|
| Ravulizumab Ultomiris® |
|
Non Formulary
|
|
|
NICE TA940: Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) NICE TA941: Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) |
|
| Satralizumab Enspryng® |
|
Non Formulary
|
|
|
NICE TA960: Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders |
|
|
Links
- Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
NHS England Urgent Clinical Commissioning Policy Statement (170018/P)- NICE HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
- NICE TA1031:Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
- NICE TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA755: Risdiplam for treating spinal muscular atrophy
- NICE TA940: Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)
- NICE TA941: Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)
- NICE TA960: Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence